BioSpace News Archive

Recent M&A activity indicates a potential resurgence in the appetites of larger companies for psychiatric drug development, but experts say the space may not offer a sufficient risk-reward proposition for R&D.

As AstraZeneca looks to climb toward the top of biopharma companies by revenue by the end of the decade, smaller companies are looking to join the ranks of the unofficial Big Pharma club.

While NK cell therapies can potentially avoid the serious side effects sometimes seen with CAR T cell therapies, experts say durability may stall their path to the market.

As we near the end of second quarter of 2024, the initial public offerings among biotechs have slowed, but the market is still going strong.

Topline overall survival results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival, numerically favored datopotamab deruxtecan compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior line of therapy.

FluoGuide A/S, a biotech company specializing in precision cancer surgery, has chosen laser system for the development of photothermal therapy.

Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, is significantly expanding its production capacities for medical systems such as inhalers and autoinjectors in the United States.

Roche announced that Hitachi High-Tech and Roche have extended their partnership, committing to at least 10 years of additional collaboration.

IRLAB Therapeutics AB - a company discovering and developing novel treatments for Parkinson’s disease - announces that its Board of Directors has appointed Kristina Torfgård as the new Chief Executive Officer.

Neuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome.